FG-M108 plus capecitabine and oxaliplatin (CAPOX) for rst-line treatment of CLDN18.2+/HER2- advanced gastric/gastroesophageal junction adenocarcinoma (GC): Update results of a phase I/II trial to determine RP2D.doi:10.1200/JCO.2025.43.4_suppl.431...
CLDN18.2 is expressed in normal gastric mucosa cells and retained in G/GEJ tumor cells. FG-M108 is a monoclonal antibody specifically targeting CLDN18.2 with optimal affinity and enhanced antibody-dependent cellular cytotoxicity. FG-M108 has demonstrated potent anti-tumor activity and excellent ...
1433P A phase I/II study of FG-M108 plus capecitabine and oxaliplatin (CAPOX) as first-line (1L) treatment for patients with CLDN18.2+/HER2- advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinomadoi:10.1016/j.annonc.2024.08.1499J. Gong...